公开(公告)号：WO1996009315A1

公开(公告)日：1996-03-28

申请号：PCT/US1995012312

申请日：1995-09-21

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  PHARMACYCLICS, INC.

Inventor： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  PHARMACYCLICS, INC. ,  MAGDA, Darren ,  SESSLER, Jonathan, L. ,  IVERSON, Brent, L. ,  SANSOM, Petra, I. ,  WRIGHT, Meredith ,  MODY, Tarak, D. ,  HEMMI, Gregory, W.

IPC: C07H21/00

CPC classification number: C12N15/113 ,  A61K41/0038 ,  A61K41/0042 ,  A61K41/0076 ,  A61K47/54 ,  A61K47/546 ,  A61K49/0021 ,  A61K49/0052 ,  A61K49/0054 ,  A61K49/06 ,  A61K49/085 ,  A61K49/10 ,  A61K51/0485 ,  A61L2/0011 ,  B01J31/061 ,  B01J31/1658 ,  B01J31/1815 ,  B01J2531/025 ,  B01J2531/38 ,  C07D487/22 ,  C07H21/00 ,  C12N2310/15 ,  C12N2310/321 ,  C12N2310/3511 ,  Y10T436/147777 ,  C12N2310/3521

Abstract: Methods of cleavage of a polymer of deoxyribonucleic acid using photosensitive texaphyrins are disclosed. A preferred method of use is the site-specific cleavage of a polymer of deoxyribonucleic acid, and a preferred texaphyrin is a derivatized texaphyrin having binding specificity, in particular, a texaphyrin covalently coupled to a site-directing molecule, preferably an oligonucleotide.

Abstract translation: 公开了使用光敏泰克萨菲蛋白分解脱氧核糖核酸聚合物的方法。 优选的使用方法是脱氧核糖核酸的聚合物的位点特异性切割，并且优选的泰克萨菲瑞是具有结合特异性的衍生化泰克萨菲林，特别是共价偶联到位点定向分子，优选寡核苷酸的泰克萨菲林。

公开(公告)号：WO2013039488A1

公开(公告)日：2013-03-21

申请号：PCT/US2011/051470

申请日：2011-09-13

Applicant: PHARMACYCLICS, INC. ,  LOURY, David, J. ,  BUGGY, Joseph, J. ,  MODY, Tarak, D. ,  VERNER, Erik, J. ,  PURRO, Norbert ,  BALASUBRAMANIAN, Sriram ,  KLOOS, Ioana ,  DEPIL, Stéphane ,  LES LABORATOIRES SERVIER SAS

Inventor： LOURY, David, J. ,  BUGGY, Joseph, J. ,  MODY, Tarak, D. ,  VERNER, Erik, J. ,  PURRO, Norbert ,  BALASUBRAMANIAN, Sriram ,  KLOOS, Ioana ,  DEPIL, Stéphane

IPC: A61K31/343 ,  A61K31/166 ,  A61K31/16 ,  A61P35/00

CPC classification number: A61K31/343 ,  A61K9/14 ,  A61K9/28 ,  A61K9/70 ,  A61K31/4184 ,  A61K2300/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.

Abstract translation: 描述了给药方案，治疗方法，控制释放制剂和包括苯达莫司汀或其药学上可接受的盐和HDAC抑制剂或其药学上可接受的盐的组合疗法。

公开(公告)号：WO2013123413A2

公开(公告)日：2013-08-22

申请号：PCT/US2013/026462

申请日：2013-02-15

Applicant: PHARMACYCLICS, INC.

Inventor： BALASUBRAMANIAN, Sriram ,  MODY, Tarak, D.

IPC: A61K31/506 ,  A61K31/517 ,  A61P35/00

CPC classification number: A61K31/343 ,  A61K31/506 ,  A61K45/06 ,  A61N5/10 ,  A61K2300/00

公开(公告)号：WO2011153514A2

公开(公告)日：2011-12-08

申请号：PCT/US2011/039190

申请日：2011-06-03

Applicant: PHARMACYCLICS, INC. ,  BUGGY, Joseph, J. ,  ELIAS, Laurence ,  FYFE, Gwen ,  HEDRICK, Eric ,  LOURY, David, J. ,  MODY, Tarak, D.

Inventor： BUGGY, Joseph, J. ,  ELIAS, Laurence ,  FYFE, Gwen ,  HEDRICK, Eric ,  LOURY, David, J. ,  MODY, Tarak, D.

IPC: A61K31/519 ,  A61K31/505 ,  A61P35/02 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61K9/0014 ,  A61K9/0031 ,  A61K9/0048 ,  A61K9/0056 ,  A61K9/007 ,  A61K9/06 ,  A61K31/195 ,  A61K31/337 ,  A61K31/4184 ,  A61K31/436 ,  A61K31/437 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/573 ,  A61K31/606 ,  A61K31/664 ,  A61K31/675 ,  A61K31/69 ,  A61K31/7032 ,  A61K31/704 ,  A61K31/7076 ,  A61K39/395 ,  A61K39/39533 ,  A61K39/3955 ,  A61K45/06 ,  C07D487/04 ,  A61K2300/00

Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

Abstract translation: 本文公开了治疗癌症的方法，包括：a。 对受试者施用Btk抑制剂足以导致免疫表型定义的淋巴细胞亚群的血液增加或出现; 湾 确定来自一个或多个淋巴细胞亚群的一种或多种生物标志物的表达谱; 和c。 基于所确定的表达谱来施用第二试剂。

公开(公告)号：WO2013173518A1

公开(公告)日：2013-11-21

申请号：PCT/US2013/041242

申请日：2013-05-15

Applicant: PHARMACYCLICS, INC.

Inventor： CHEN, Wei ,  LOURY, David, J. ,  MODY, Tarak, D.

IPC: C07D239/48 ,  A61K31/505 ,  A61P37/00

CPC classification number: C07D239/48 ,  A61K31/505

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

公开(公告)号：WO2013010136A2

公开(公告)日：2013-01-17

申请号：PCT/US2012/046779

申请日：2012-07-13

Applicant: PHARMACYCLICS, INC. ,  CHEN, Wei ,  LOURY, David, J. ,  MODY, Tarak, D. ,  WANG, Longcheng

Inventor： CHEN, Wei ,  LOURY, David, J. ,  MODY, Tarak, D.

IPC: A61K31/52 ,  A61K31/433 ,  C07D473/34 ,  C07D473/32 ,  A61P17/00 ,  A61P29/00

CPC classification number: C07D487/04 ,  A61K31/52 ,  C07D473/34

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

Abstract translation: 本文描述了激酶抑制剂化合物，用于合成这种抑制剂的方法，以及使用这些抑制剂治疗疾病的方法。 本文进一步描述了用于确定蛋白质的合适抑制剂（包括激酶）的方法，测定法和系统。

公开(公告)号：WO2004050716A2

公开(公告)日：2004-06-17

申请号：PCT/US2003/037888

申请日：2003-11-24

Applicant: PHARMACYCLICS, INC. ,  DOUGLAS, Cary ,  FU, Lei ,  MODY, Tarak, D.

Inventor： DOUGLAS, Cary ,  FU, Lei ,  MODY, Tarak, D.

IPC: C08F

CPC classification number: C07D487/22

Abstract: The present invention provides a process for replacing a metal cation, M 1 , from a compound of Formula I.

Abstract translation: 本发明提供了从式I化合物代替金属阳离子M 1的方法。

公开(公告)号：EP0745085B1

公开(公告)日：2002-05-22

申请号：EP95911776.3

申请日：1995-02-15

Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM ,  PHARMACYCLICS, INC.

Inventor： SESSLER, Jonathan, L. ,  MODY, Tarak, D. ,  HEMMI, Gregory, W.

IPC: C07D487/22 ,  A61K49/00

CPC classification number: C07D487/22 ,  A61K41/0009 ,  A61K41/0038 ,  A61K41/0076 ,  A61K49/0021 ,  A61K49/106 ,  A61K51/04 ,  A61K51/0485 ,  A61K51/1093 ,  A61K2121/00 ,  A61L2/0011 ,  C07H21/00

Abstract: Texaphyrin metal complexes of formula (I) having improved functionalization include the addition of electron donating groups to positions 2, 7, 12, 15, 18 and/or 21 and/or the addition of electron withdrawing groups to positions 15 or 18 of the macrocycle. Electron donating groups at positions 2, 7, 12, 15, 18 and/or 21 contribute electrons to the aromatic π system of the macrocycle which stabilizes the metal complex to demetallation and the imine bonds to hydrolysis. These texaphyrin metal complexes having enhanced stability are useful for localization, magnetic resonance imaging, radiosensitization, radiation therapy, fluorescence imaging, photodynamic tumor therapy and applications requiring singlet oxygen production for cytotoxicity. Electron withdrawing groups at positions 15 or 18 render the macrocycle more readily reduced, i.e. the redox potential is lower and the macrocycle more readily gains an electron to form a radical. Such texaphyrins having a low redox potential are useful for radiosensitization applications.

公开(公告)号：EP2731612A2

公开(公告)日：2014-05-21

申请号：EP12811600.1

申请日：2012-07-13

Applicant: Pharmacyclics, Inc.

Inventor： CHEN, Wei ,  LOURY, David, J. ,  MODY, Tarak, D. ,  WANG, Longcheng

IPC: A61K31/52 ,  A61K31/433 ,  C07D473/34 ,  C07D473/32 ,  A61P17/00 ,  A61P29/00

CPC classification number: C07D487/04 ,  A61K31/52 ,  C07D473/34

Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.

公开(公告)号：EP2755648A1

公开(公告)日：2014-07-23

申请号：EP11872389.9

申请日：2011-09-13

Applicant: Pharmacyclics, Inc. ,  Les Laboratoires Servier SAS

Inventor： LOURY, David, J. ,  BUGGY, Joseph, J. ,  MODY, Tarak, D. ,  VERNER, Erik, J. ,  PURRO, Norbert ,  BALASUBRAMANIAN, Sriram ,  KLOOS, Ioana ,  DEPIL, Stéphane

IPC: A61K31/343 ,  A61K31/166 ,  A61K31/16 ,  A61P35/00

CPC classification number: A61K31/343 ,  A61K9/14 ,  A61K9/28 ,  A61K9/70 ,  A61K31/4184 ,  A61K2300/00

Abstract: Dosing regimens, methods of treatment, controlled release formulations, and combination therapies that include bendamustine, or a pharmaceutically acceptable salt thereof and an HDAC inhibitor, or a pharmaceutically acceptable salt thereof, are described.